Buy NTLA by Sep 12, 2026.

**Positions:** Long NTLA. This is a fundamental and structural analysis of a major dislocation in the biotech sector that materialized today (Saturday, June 13). The market has fundamentally mispriced **Intellia Therapeutics (NASDAQ: NTLA)** due to a recent secondary offering, creating a highly asymmetric risk/reward profile ahead of Monday's opening. Here is the objective breakdown of the clinical data and the market mechanics. # 1. The Technology: In-Vivo vs. Ex-Vivo To understand the valuation gap, you have to separate the two …